Pivotal trials of the currently most effective triple combination CFTR modulator therapy of elexacaftor, tezacaftor, and ivacaftor (ETI) demonstrated unprecedented improvements in clinical outcomes, including pulmonary function and quality of life in CF patients with 1 or 2 F508del alleles (13–16). Here, CFTR is linked to cystic fibrosis.